InvestorsHub Logo
Post# of 6214
Followers 46
Posts 4493
Boards Moderated 0
Alias Born 07/26/2010

Re: None

Saturday, 06/15/2024 2:46:45 PM

Saturday, June 15, 2024 2:46:45 PM

Post# of 6214
VXRT .62 - Up to $453 million to Vaxart of San Francisco, California, developing an oral pill vaccine candidate, adenovirus serotype 5 (Ad-5). BARDA will provide an initial $65.7 million for early trial milestones, with remaining funds provided as the effort successfully advances toward trial execution. Vaxart will execute its own Phase 2b clinical trials.

https://www.hhs.gov/about/news/2024/06/13/barda-awards-500-million-project-nextgen-funding-vaccine-clinical-trials.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VXRT News